Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial

scientific article published on 19 July 2018

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.2337/DC18-0623
P698PubMed publication ID30026335

P50authorParesh DandonaQ29447364
Pieter GillardQ56811703
Serge JabbourQ87858486
Chantal MathieuQ88112330
Marcus LindQ89461797
P2093author name stringPeter Senior
Lars Hansen
Eiichi Araki
Niki Arya
Christoph Hasslacher
Stephen C Bain
Anna Maria Langkilde
Fredrik Thorén
DEPICT-2 Investigators
P433issue9
P407language of work or nameEnglishQ1860
P921main subjecttype-1 diabetesQ124407
P304page(s)1938-1946
P577publication date2018-07-19
P1433published inDiabetes CareQ5270111
P1476titleEfficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial
P478volume41

Reverse relations

cites work (P2860)
Q90043452Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update
Q64231829Combination Therapy with Empagliflozin and Insulin Results in Successful Glycemic Control: A Case Report of Uncontrolled Diabetes Caused by Autoimmune Pancreatitis and Subsequent Steroid Treatment
Q97682132Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes
Q64767149Comparison of pharmacokinetics and the exposure-response relationship of dapagliflozin between adolescent/young adult and adult patients with type 1 diabetes mellitus
Q57822742Developments in the Management of Type 1 and Type 2 Diabetes
Q90398929Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes
Q99569227Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials
Q93030859Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials
Q92583713Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double-blind, phase 3 trial
Q64904716Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy.
Q92304196Glycaemic variability: The under-recognized therapeutic target in type 1 diabetes care
Q92964215HbA1c level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study
Q92126784Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program
Q64385669International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors
Q92139553Low-dose empagliflozin as adjunct-to-insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy
Q92737259Lower Renal Threshold for Glucose Reabsorption in Type 1 Diabetes Mellitus (T1DM) May Explain the Smaller Contribution of SGLT2 Inhibitors to the Improvement of Plasma Glucose Control Compared with T2DM
Q64780233Model-based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus
Q93130541NICE guidance on dapagliflozin with insulin for type 1 diabetes
Q91778233Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
Q91984134Past, present and future of latent autoimmune diabetes in adults
Q93382017Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes
Q89465090Renal physiology of glucose handling and therapeutic implications
Q93221847Risk factors and prevention strategies for diabetic ketoacidosis in people with established type 1 diabetes
Q98386639SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects
Q90491155SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks
Q91970275Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials
Q89890479Sodium-glucose cotransporter 2 inhibitors improved time-in-range without increasing hypoglycemia in Japanese patients with type 1 diabetes: A retrospective, single-center, pilot study
Q92117496Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes
Q91977138Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption
Q89499060The mechanism of hsa-miR-424-5 combining PD-1 through mTORC signaling pathway to stimulate immune effect and participate in Type 1 diabetes
Q64816409Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitus

Search more.